“Efficacy and Safety by Body Weight Decile in Patients Treated With Tildrakizumab 100 Mg for 28 Weeks: Pooled Data Analysis of ReSURFACE 1 and ReSURFACE 2”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s136, https://doi.org/10.25251/skin.7.supp.136.